Zecuity® (sumatriptan iontophoretic transdermal system) – Product Discontinuation

- On October 19, 2017, the FDA announced the discontinuation of Teva's Zecuity (sumatriptan iontophoretic transdermal system).
    - In June 2016, Teva announced the voluntary suspension of sales, marketing and distribution of Zecuity due to postmarketing reports of application site reactions including severe redness, cracked skin, blistering or welts, and burns or scars associated with the product.
    - Teva advised healthcare providers to discontinue use of Zecuity and a pharmacy-level recall of Zecuity was conducted.
- Zecuity is indicated for the acute treatment of migraine with or without aura in adults.
- Sumatriptan is currently available as Imitrex® nasal spray, Imitrex® solution for injection, Onzetra™ Xsail™ nasal powder, Zembrace™ SymTouch™ autoinjector, and Imitrex® oral tablet. The nasal spray, solution for injection, and oral tablets are available generically.
    - Refer to individual drug labels for specific indication and dosage information.
- There was no Zecuity utilization in the 3rd quarter of 2017.

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.